GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Price to Book Ratio (P/B) on January 27, 2025: 3.50

GuiZhou SanLi Pharmaceutical Co.,Ltd Price to Book Ratio (P/B) is 3.50 on January 27, 2025, a -24.26% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

GuiZhou SanLi Pharmaceutical Co.,Ltd 52-week high Price to Book Ratio (P/B) is 4.88 on March 18, 2024, which is 39.44% above the current Price to Book Ratio (P/B).
GuiZhou SanLi Pharmaceutical Co.,Ltd 52-week low Price to Book Ratio (P/B) is 3.02 on August 23, 2024, which is -13.71% below the current Price to Book Ratio (P/B).
GuiZhou SanLi Pharmaceutical Co.,Ltd average Price to Book Ratio (P/B) for the last 52 weeks is 3.83.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years